Tagged with Novartis

Italy The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine contracts, glass vial manufacturer Stevenato’s USD five billion valuation, AIFA’s approval of Novartis’s Zolgensma, and how Italy has become the first EU country to manufacture Russia’s Sputnik V vaccine.   COVID-19 vaccine vial maker Stevanato…

China Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into a regular national and provincial exercise, lopping off over a billion dollars from the top lines of both multinational and…

Global The Top 20 companies on the 2021 Access to Medicines Index ranked on governance of access, research and development, and product delivery indices. Compiled by the Access to Medicine Foundation, the report measures how well the largest 20 global Big Pharma companies are making drugs and vaccines accessible to low-…

Global Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has put in place for the business, and the key issues of manufacturing and access.   Cell and gene therapies are truly…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

InFocus BACK TO HOME     Cell & Gene Therapy   BACK TO HOME Stefan Hendriks Global Head, Cell & Gene, Novartis Oncology Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he…

Global The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these local insights help give a more well-rounded global picture of our industry today.   1. Bill Sibold, Executive VP, Sanofi…

USA With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business transformation in the past few years, and if the business unit’s 2019 performance is anything to go by, the efforts have paid off, with net sales reaching USD 14.4…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement models like ‘pay-for-performance’ agreements and the implementation challenges of such initiatives. The session was moderated by FT reporter Donato Mancini and saw the participation of Novartis Oncology president Dr Susanne Schaffert; bluebird…

Global Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight, and makes three bold predictions for the future of the field, especially in emerging countries.   As a true believer in the power of technology to transform health,…

Opinion Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the myriad benefits of collaborative, as opposed to command, leadership, the impact of company and team culture on the innovation journey, and why we must not confuse collaboration with…

Saudi Arabia The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10 corporations account for 50 percent of total sales in the USD 8.2 billion Saudi pharma market. Global giants Pfizer, Sanofi, and Novartis make up the top three spots, but…